To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
April 2013

Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy

Vol: 2| Issue: 3| Number:12| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma

Cancer. 2012 Dec 1;118(23):5888-93

Contributing Authors:
NM Bernthal N Federman FR Eilber SD Nelson JJ Eckardt FC Eilber WD Tap

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...

Join the Conversation

Please Login or Join to leave comments.